This trial is unknown status.

Condition methamphetamine dependence
Treatment lobeline
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date February 2006
Trial size 12 participants
Trial identifier NCT00519259, NIDA-CPU-0009-1


The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety study
Intervention model single group assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

time frame:

Secondary Outcomes

time frame:
Pharmacokinetic parameters
time frame:
Cardiovascular responses
time frame:
Psychological effects of lobeline
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: - Must be able to provide written informed consent - Must have a body mass index between 18 and 30 - Have no medical contraindications as determined by medical history, physical exam, ECG, hematology and blood chemistry profile, and urinalysis - Must have a negative drug test at screening and admission - If female of child bearing potential, must agree to use birth control Exclusion Criteria: - Please contact the site for more information

Additional Information

Official title Tolerability, Safety, and Pharmacokinetics of Repeated Sublingual Doses of Lobeline
Principal investigator Reese Jones, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).